Furthermore, downregulation of antiapoptotic Bcl-2 proteins (Bcl-2, Mcl-1, and Bcl-xL) was reported in melanoma cells upon treatment with different therapeutic strategies used for TRAIL sensitization, such as chemotherapeutics and inhibitors for metabolism, HDACs, and kinases. This evidence concerns the gene BCL2L1 and melanoma.